Janux Therapeutics Doses First Patient in JANX014 Study
SAN DIEGO, USA, April 16, 2026 Janux Therapeutics, Inc. has announced a key clinical milestone with the first participant...
prostate cancer
Advertisement
Clarity Signs Deal to Boost Prostate Cancer Imaging Supply
Sydney, Australia | April 14, 2026 Clarity Pharmaceuticals has announced the signing of a Commercial Manufacturing Agreement with Nucleus...
Adagene Reports Strong Muzastotug KEYTRUDA CRC Data
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
IDEAYA Biosciences Doses First Patient in IDE574 Trial
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
Clarity Co-PSMA Shows Superior Prostate Cancer Detection
SYDNEY, Australia, March 31, 2026 Clarity Pharmaceuticals has announced the publication of Phase II Co-PSMA clinical trial results in...
Advertisements
Pfizer TALZENNA XTANDI Boost Survival in Prostate Cancer
NEW YORK, March 19, 2026 Pfizer Inc. announced that its Phase 3 TALAPRO-3 clinical trial evaluating TALZENNA® (talazoparib) in...
Pasritamig Shows Strong Phase 1b Results in mCRPC
RARITAN, N.J., February 26, 2026 Johnson & Johnson announced encouraging preliminary results from a Phase 1b clinical study evaluating...
J&J Pasritamig Combo Shows Strong mCRPC Activity
RARITAN, N.J., February 26, 2026 Johnson & Johnson (NYSE: JNJ) announced preliminary Phase 1b clinical results demonstrating promising antitumor...
SECuRE Trial: Undetectable Disease With 67Cu-SAR-bisPSMA
SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting...
Trinity Boosts EpiCapture Test with Advanced Epigenetic Analytics
Dateline: November 14, 2025 — Dublin, IrelandTrinity Biotech has announced a strategic collaboration with a leading bioinformatics partner to...
Advertisement
